# Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

> **NCT03834961** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 33 (actual)

## Conditions studied

- Central Nervous System Neoplasm
- Infantile Fibrosarcoma
- Recurrent Acute Leukemia
- Refractory Acute Leukemia
- Solid Neoplasm

## Interventions

- **DRUG:** Larotrectinib Sulfate

## Key facts

- **NCT ID:** NCT03834961
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-25
- **Primary completion:** 2024-09-30
- **Final completion:** 2027-07-25
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834961, "Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT03834961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*